FDA Grants Priority Review for Shire's velaglucerase alfa for Type 1 Gaucher Disease
4th November 2009 CAMBRIDGE, Massachusetts, November 4 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced that the United States Food and
Drug...
MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
3rd November 2009 WILMINGTON, Delaware, November 3 /PRNewswire/ -- The new market research report, 'Global Stem Cell and Advanced
Technologies Market' (2009 - 2014)', published by...
Abbott's XIENCE PRIME(TM) and XIENCE V(R) Receive Indications in Europe for Treatment of Patients with Diabetes
2nd November 2009 BRUSSELS, November 2 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that both the XIENCE PRIME(TM)
Everolimus Eluting Coronary Stent System(1) and the XIENCE V(R) Everolimus
Eluting Coronary...
Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc.
2nd November 2009 COPENHAGEN, November 2 /PRNewswire/ -- Nuevolution A/S today announced that it has received a milestone payment
derived from its collaboration with Merck & Co. Inc., Whitehouse Station, NJ.
The...
/C O R R E C T I O N -- CeloNova BioSciences, Inc./
31st October 2009 NEWNAN, Georgia, October 31 /PRNewswire/ -- In the news release, French Physicians to Conduct 2000-Patient Study of
CATANIA(TM) Coronary Stent, issued Oct. 30, 2009, by CeloNova
BioSciences, Inc.,...
French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent
30th October 2009 NEWNAN, Georgia, October 30 /PRNewswire/ -- Physicians at more than 40 centers in France have joined a study of the
CATANIA(TM) Coronary Stent with NanoThin Polyzene(R)-F manufactured by
CeloNova...
Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Survival
30th October 2009 LONDON, October 30 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito)
today announced preliminary results from a recently completed Phase III study
with E7389...
AMT Starts Development LPLChip(TM) With Progenika
29th October 2009 AMSTERDAM, October 29 /PRNewswire/ -- Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced
today that the companies have entered into a development and
commercialization agreement...
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
28th October 2009 DUBLIN, October 28 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today announced it has received approval through
the European Mutual...
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
28th October 2009 LEUVEN, Belgium and LUND, Sweden, October 28 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development
partner BioInvent International (OMXS: BINV) announce that they...
BornFree Baby Bottles Borne Into Britain
28th October 2009 LONDON, October 28 /PRNewswire/ -- Parents looking to protect their babies from potentially harmful
chemicals are today being advised to buy BornFree(TM), the world's leading
brand for baby bottles...
Simbionix Introduces the Next Generation in Bronchoscopy Training
27th October 2009 CLEVELAND, Ohio, October 27 /PRNewswire/ -- Simbionix, the world's leading developer of medical simulation
systems, introduces it's new advanced simulator, the GI-BRONCH Mentor, a
comprehensive...
Video: One Shot of Gene Therapy and Children with Congenital Blindness Can Now See
24th October 2009 PHILADELPHIA, October 24 /PRNewswire/ -- Born with a retinal disease that made him legally blind, and would
eventually leave him totally sightless, the nine-year-old boy used to sit in
the back of...
Cohera Medical, Inc. Receives Approval To Begin Human Clinical Trials of TissuGlu(R) in Europe
23rd October 2009 PITTSBURGH, October 23 /PRNewswire/ -- Cohera Medical, Inc. announced today that it has received approval to
begin human clinical trials of its lead product TissuGlu(R) in Germany.
Receipt of the...
Research Into Cancer During Pregnancy: Treating Pregnant Women With Chemotherapy has no Detrimental Effect on the Foetus
23rd October 2009 LEUVEN, Belgium, October 23 /PRNewswire/ -- Professor Frederic Amant of the Katholieke Universiteit Leuven
(K.U.Leuven) directs research into the treatment of cancer in pregnant women
and the...
First Intra-Arrest Cooling Study Chosen for AHA Scientific Sessions Late Breaking Presentation
22nd October 2009 SAN DIEGO, October 22 /PRNewswire/ -- The first randomized intra-arrest cooling study has been selected for
presentation as a Late Breaking trial during the American Heart Association's
Scientific...
ADVANCE Reveals New Insights in the Fight Against Severe Diabetes Complications
20th October 2009 MONTREAL, October 20 /PRNewswire/ -- New results from ADVANCE (Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial
ever performed in...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
